<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Once the diagnosis of a thrombophilic state has been established, management must include one or more strategies designed to attenuate thrombotic risk and the likelihood of clinical events </plain></SENT>
<SENT sid="1" pm="."><plain>In the case of drug-induced <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> provoked by oral contraceptives, hormone replacement therapy, heparinoids, cocaine, or <z:chebi fb="0" ids="37942">thienopyridine</z:chebi>-related thrombotic thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo> (<z:chebi fb="1" ids="18284">TTP</z:chebi>), the offending agent should be discontinued immediately </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="3" ids="50249">Anticoagulant</z:chebi> therapy and platelet-directed therapies, either alone or in combination, should be considered for patients experiencing a single arterial or <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> (secondary prevention), with treatment duration determined by diagnostic studies and the persistence of a prothrombotic state </plain></SENT>
<SENT sid="3" pm="."><plain>Other specific therapies should be directed at the underlying thrombophilic disorder </plain></SENT>
<SENT sid="4" pm="."><plain>These treatments include direct thrombin inhibitors such as argatroban for <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> (HIT), myelosuppressive drugs such as <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> for essential <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo>, plasma exchange for thrombotic thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo>, and phlebotomy for <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera </plain></SENT>
<SENT sid="5" pm="."><plain>Additionally, the treating physician must seek input early from a hematologist or rheumatologist when managing patients with known or suspected HIT, <z:chebi fb="1" ids="18284">TTP</z:chebi>, and <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo>, or the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>This interdisciplinary interface is critical to ensure an optimal outcome when treating patients with arterial <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> </plain></SENT>
</text></document>